Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01870869
Recruitment Status : Terminated (There was no indication that long-term follow-up would differ between any of the studies that have evaluated devices within the 410 Style Matrix.)
First Posted : June 6, 2013
Results First Posted : June 22, 2020
Last Update Posted : June 22, 2020
Sponsor:
Information provided by (Responsible Party):
Allergan

Brief Summary:
This study is a prospective, multicenter, nonrandomized study to provide access to and evaluate the safety and effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X-Style and L-Style Breast Implants for breast augmentation, reconstruction, or revision.

Condition or disease Intervention/treatment Phase
Breast Augmentation Breast Reconstruction Breast Implant Revision Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1951 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study
Actual Study Start Date : May 29, 2013
Actual Primary Completion Date : November 30, 2015
Actual Study Completion Date : November 30, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Augmentation
Women who had breast augmentation with NATRELLE® 410 implants.
Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Surgical implant
Other Name: NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles FX, MX, LX, FL, ML, LL, LM, and LF)

Experimental: Reconstruction
Women who had breast reconstruction with NATRELLE® 410 implants.
Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Surgical implant
Other Name: NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles FX, MX, LX, FL, ML, LL, LM, and LF)

Experimental: Revision-Augmentation
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Surgical implant
Other Name: NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles FX, MX, LX, FL, ML, LL, LM, and LF)

Experimental: Revision-Reconstruction
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Surgical implant
Other Name: NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles FX, MX, LX, FL, ML, LL, LM, and LF)




Primary Outcome Measures :
  1. Percentage of Participants According to Investigator Satisfaction With Implants [ Time Frame: 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) ]
    The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: "Definitely satisfied" or "Somewhat satisfied" is reported.

  2. Percentage of Participants According to Participant Satisfaction With Implants [ Time Frame: 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) ]
    The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: "Definitely satisfied" or "Somewhat satisfied" is reported.


Secondary Outcome Measures :
  1. Percentage of Participants With Local Complications [ Time Frame: 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) ]
    Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .

  2. Percentage of Participants With Reoperations [ Time Frame: 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) ]
    Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.

  3. Percentage of Participants With Implant Removal With or Without Replacement [ Time Frame: 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) ]
    Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study under the inclusion criteria below and received NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts; or be planning to be implanted with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and meet the inclusion criteria listed below:

  • Female, age 18 or older (age 22 or older for breast augmentation participants who are implanted under Protocol 410CAXL-001)
  • Present with 1 or more of the following conditions:

    • Primary breast augmentation (i.e., no previous breast implant surgery) indicated for participant dissatisfaction with size or shape of breast (e.g., mammary hypoplasia), asymmetry, ptosis, or aplasia
    • Primary breast reconstruction (i.e., no previous breast implant surgery other than implantation of tissue expanders or contralateral augmentation for asymmetry) indicated, in the affected breast, for mastectomy for cancer, prophylactic mastectomy, or breast trauma, (resulting in mastectomy) and for the unaffected breast, contralateral asymmetry (may be performed on the date of the mastectomy or the date when permanent implants are placed in the reconstructed breast)
    • Breast implant revision surgery (i.e., removal and replacement of breast implants) indicated for previous augmentation or reconstruction with silicone-filled or saline-filled breast implants
  • Has adequate tissue available to cover implants

Exclusion Criteria:

For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study and did not meet the exclusion criteria listed below or plan to undergo implantation with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and does not meet the exclusion criteria listed below:

  • Has an advanced fibrocystic disease considered to be premalignant without accompanying subcutaneous mastectomy
  • Has an existing carcinoma of the breast, without mastectomy
  • Has an abscess or infection in the body at the time of enrollment
  • Is pregnant or nursing
  • Has any disease, including uncontrolled diabetes (e.g., hemoglobin A1c (HbA1c) > 8%), that is clinically known to impact wound healing ability
  • Shows tissue characteristics that are clinically incompatible with mammaplasty, such as tissue damage resulting from radiation, inadequate tissue, compromised vascularity, or ulceration
  • Has or is under treatment for any condition that may constitute an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)
  • Shows psychological characteristics that may be incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body dysmorphic disorder)
  • Is not willing to undergo further surgery for revision, if medically required

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870869


Locations
Show Show 58 study locations
Sponsors and Collaborators
Allergan
Investigators
Layout table for investigator information
Study Chair: Andrew Schumacher Allergan
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01870869    
Other Study ID Numbers: 410CAXL-001
First Posted: June 6, 2013    Key Record Dates
Results First Posted: June 22, 2020
Last Update Posted: June 22, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: Yes